Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225-macropa-pelgifatamab
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Actinium-225-macropa-pelgifatamab (BAY3546828) is a targeted alpha therapy (TAT) being developed by Bayer for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug is a radiopharmaceutical conjugate consisting of a monoclonal antibody, pelgifatamab, which specifically targets the prostate-specific membrane antigen (PSMA) expressed on the surface of prostate cancer cells. This antibody is linked via a macropa chelator to the alpha-emitting radioisotope actinium-225. Upon binding to PSMA-positive cells, the actinium-225 delivers high-energy, short-range alpha radiation, causing lethal double-strand DNA breaks in the target cancer cells while minimizing damage to surrounding healthy tissue. It is currently being evaluated in Phase 1 clinical trials for patients with advanced mCRPC who have limited treatment options.
- Other names
- Actinium-225 pelgifatamabActinium225 pelgifatamabActinium 225 pelgifatamab225Ac-macropa-pelgifatamab
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on actinium-225-macropa-pelgifatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225-macropa-pelgifatamab.